Literature DB >> 1987770

Mature eosinophils stimulated to develop in human cord blood mononuclear cell cultures supplemented with recombinant human interleukin-5. Part I. Piecemeal degranulation of specific granules and distribution of Charcot-Leyden crystal protein.

A M Dvorak1, T Furitsu, L Letourneau, T Ishizaka, S J Ackerman.   

Abstract

Human cord blood mononuclear cells were cultured for 35 days in media containing recombinant human interleukin 5 (rhIL-5) supplemented with a fraction of the culture supernatant of phytohemagglutinin (PHA)-stimulated human T lymphocytes from which interleukin 2 (IL-2) was eliminated. Cultured cells were studied by electron microscopy and an immunogold procedure to detect subcellular site(s) of Charcot-Leyden crystal (CLC) protein. The majority of cells (greater than 70%) developing in this system were mature eosinophils, with descending frequency of other cells, including macrophages, mature basophils, eosinophilic myelocytes, and mature neutrophils. Mature eosinophils were characterized by increased numbers of primary granules, small granules, tubulovesicular structures, and decreased secondary granules. These eosinophils showed extensive piecemeal degranulation (PMD) characterized by partially empty and empty secondary granule chambers in the cytoplasm. Small, smooth vesicles were evident within empty granule chambers as well as adjacent to them. Eosinophils formed close associations with phagocytic macrophages that contained both standard-shaped and irregularly shaped CLC within phagolysosomes. Subcellular sites of CLC protein were demonstrated by immunogold in eosinophils and macrophages arising in these cultures. Charcot-Leyden crystal protein was present in the nuclear matrix and extraorganellar cytoplasm of eosinophils. Primary granules and some cytoplasmic vesicles were labeled for CLC protein, but full and empty secondary granules and the extensive network of tubulovesicles were not. Charcot-Leyden crystals were absent from eosinophils, nor were they present in the extracellular space. Charcot-Leyden crystals were absent from eosinophils, nor were they present in the extracellular space. Charcot-Leyden crystals within phagosomes of macrophages were labeled by the immunogold procedure for CLC protein. These results demonstrate that rhIL-5-supplemented, PHA-stimulated, T-cell-conditioned media induced the development of mature human eosinophils from cord blood cells. These eosinophils underwent PMD of secondary granule contents. Immunogold analysis showed eosinophil CLC protein in the cytoplasm, nucleus, and primary granules of eosinophils. Macrophages also were present in these cultures. They contained CLC protein-containing crystals in their phagosomes, suggesting active sequestration of eosinophil CLC protein by macrophages in vitro.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1987770      PMCID: PMC1886056     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  57 in total

Review 1.  Preferential differentiation of inflammatory cells by recombinant human interleukins.

Authors:  T Ishizaka; H Saito; K Hatake; A M Dvorak; K M Leiferman; N Arai; K Ishizaka
Journal:  Int Arch Allergy Appl Immunol       Date:  1989

2.  Isolation and characterization of lymphokine cDNA clones encoding mouse and human IgA-enhancing factor and eosinophil colony-stimulating factor activities: relationship to interleukin 5.

Authors:  T Yokota; R L Coffman; H Hagiwara; D M Rennick; Y Takebe; K Yokota; L Gemmell; B Shrader; G Yang; P Meyerson
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

3.  Comparative effect of recombinant IL-1, -2, -3, -4, and -6, IFN-gamma, granulocyte-macrophage-colony-stimulating factor, tumor necrosis factor-alpha, and histamine-releasing factors on the secretion of histamine from basophils.

Authors:  R Alam; J B Welter; P A Forsythe; M A Lett-Brown; J A Grant
Journal:  J Immunol       Date:  1989-05-15       Impact factor: 5.422

4.  Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins.

Authors:  H Saito; K Hatake; A M Dvorak; K M Leiferman; A D Donnenberg; N Arai; K Ishizaka; T Ishizaka
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

5.  Differential effects of interleukin-1 alpha and interleukin-1 beta on human peripheral blood eosinophils.

Authors:  E A Whitcomb; C A Dinarello; S H Pincus
Journal:  Blood       Date:  1989-05-15       Impact factor: 22.113

6.  Ultrastructural localization of the Charcot-Leyden crystal protein (lysophospholipase) to granules and intragranular crystals in mature human basophils.

Authors:  A M Dvorak; S J Ackerman
Journal:  Lab Invest       Date:  1989-04       Impact factor: 5.662

7.  Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3.

Authors:  M E Rothenberg; W F Owen; D S Silberstein; J Woods; R J Soberman; K F Austen; R L Stevens
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

8.  IgA-induced eosinophil degranulation.

Authors:  R I Abu-Ghazaleh; T Fujisawa; J Mestecky; R A Kyle; G J Gleich
Journal:  J Immunol       Date:  1989-04-01       Impact factor: 5.422

9.  Ultrastructural localization of the Charcot-Leyden crystal protein (lysophospholipase) to a distinct crystalloid-free granule population in mature human eosinophils.

Authors:  A M Dvorak; L Letourneau; G R Login; P F Weller; S J Ackerman
Journal:  Blood       Date:  1988-07       Impact factor: 22.113

10.  Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF.

Authors:  E J Clutterbuck; E M Hirst; C J Sanderson
Journal:  Blood       Date:  1989-05-01       Impact factor: 22.113

View more
  31 in total

Review 1.  Mechanisms of eosinophil cytokine release.

Authors:  Christianne Bandeira-Melo; Peter F Weller
Journal:  Mem Inst Oswaldo Cruz       Date:  2005-06-14       Impact factor: 2.743

Review 2.  Contributions of electron microscopy to understand secretion of immune mediators by human eosinophils.

Authors:  Rossana C N Melo; Ann M Dvorak; Peter F Weller
Journal:  Microsc Microanal       Date:  2010-09-27       Impact factor: 4.127

Review 3.  Mechanisms of eosinophil secretion: large vesiculotubular carriers mediate transport and release of granule-derived cytokines and other proteins.

Authors:  Rossana C N Melo; Lisa A Spencer; Ann M Dvorak; Peter F Weller
Journal:  J Leukoc Biol       Date:  2007-09-17       Impact factor: 4.962

4.  Reply to eosinophil cytolysis and release of cell-free granules.

Authors:  Helene F Rosenberg; Paul S Foster
Journal:  Nat Rev Immunol       Date:  2013-12       Impact factor: 53.106

Review 5.  "Ultimate activation" of eosinophils in vivo: lysis and release of clusters of free eosinophil granules (Cfegs).

Authors:  C G Persson; J S Erjefält
Journal:  Thorax       Date:  1997-06       Impact factor: 9.139

6.  Molecular Biology of Eosinophils: Introduction.

Authors:  Paige Lacy; Helene F Rosenberg; Garry M Walsh
Journal:  Methods Mol Biol       Date:  2021

7.  Murine lung eosinophil activation and chemokine production in allergic airway inflammation.

Authors:  C Edward Rose; Joanne A Lannigan; Paul Kim; James J Lee; Shu Man Fu; Sun-sang J Sung
Journal:  Cell Mol Immunol       Date:  2010-07-12       Impact factor: 11.530

8.  Ultrastructural morphology, cytochemistry, and morphometry of eosinophil granules in Chédiak-Higashi syndrome.

Authors:  S C Hamanaka; C S Gilbert; D A White; R T Parmley
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

Review 9.  Functional role of eosinophils in gastrointestinal inflammation.

Authors:  Simon P Hogan
Journal:  Immunol Allergy Clin North Am       Date:  2009-02       Impact factor: 3.479

Review 10.  Functional extracellular eosinophil granules: novel implications in eosinophil immunobiology.

Authors:  Josiane S Neves; Peter F Weller
Journal:  Curr Opin Immunol       Date:  2009-08-24       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.